NasdaqGM:SUPNPharmaceuticals
How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Raising 2025 Revenue Guidance Despite Net Losses
Supernus Pharmaceuticals, Inc. reported third quarter 2025 earnings, showing revenue of US$192.1 million and a net loss of US$45.12 million, and subsequently raised its full-year 2025 revenue guidance to US$685 million–US$705 million while narrowing projected operating losses.
This updated outlook reflects the company’s increased confidence in its operating performance despite continuing challenges with net losses and higher expenses.
We’ll explore how Supernus Pharmaceuticals’ upward...